See the DrugPatentWatch profile for Uzedy
Uzedy, a medication for managing chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), is administered as a subcutaneous injection with a dosage schedule of six injections per year [1]. This regimen translates to one injection every two months [2].
How is Uzedy administered?
Uzedy is given as a subcutaneous injection [1]. Patients receive six injections annually, which means an injection is administered every two months [2].
What is Uzedy used to treat?
Uzedy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) [1].
How does Uzedy work?
Uzedy is a bispecific antibody designed to target both CD20 and CD3. By binding to these targets, it redirects T-cells to induce cell death in CD20-positive malignant cells [3].
When does Uzedy's patent expire?
Information regarding the specific patent expiry dates for Uzedy is not publicly available in the provided context. DrugPatentWatch.com tracks pharmaceutical patent information and can be a resource for such details [4].
What are the alternatives to Uzedy for CLL and SLL?
Treatment options for CLL and SLL can vary. Other medications and therapies are available, and the choice of treatment depends on individual patient factors and disease characteristics. Consult a healthcare professional for personalized treatment advice [5].